Melanoma-Associated Antigen-A (MAGE-A3/A6) -Specific Monoclonal Antibody

A T cell receptor (TCR) recognizing melanoma-associated antigen-A (MAGE-A3/A6) is currently used in clinical trials involving adoptive transfer of TCR-transduced T cells for patients with metastatic cancer. To be eligible for this TCR immunotherapy, tumor specimens from patients must show homogeneous expression of MAGE-A3 and/or MAGE-A6. Currently-available antibodies recognize additional members of the MAGE-A family and/or are cross-reactive because they were raised by epitopes shared among the MAGE-A family members.MAGE-A3 and MAGE-A6 are members of the MAGE-A family of twelve homologous proteins. The MAGE-A proteins are cancer testis antigens (CTA) that are expressed only in tumor cells and non-MHC expressing germ cells of the testis and placenta. MAGE-A3 and MAGE-A6 proteins are expressed in a variety of human cancers including, but not limited to, melanoma, leukemia, multiple myeloma, synovial cell sarcoma, urothelial cancer and cancers of the breast, thyroid, stomach, pancreas, liver (e.g., hepatocellular carcinoma), lung (e.g., non-small cell lung carcinoma), ovaries, , esophagus, kidney, head (e.g., squamous cell carcinoma), neck (e.g., squamous cell carcinoma), and prostate.  Researchers at the National Cancer Institute (NCI)   developed a monoclonal antibody against MAGE-A3/A6, where the antibody and antigen binding fragment specifically bind to human MAGE-A3 and human MAGE-A6, and the antibody is a rabbit antibody. The antibody can be used for screening patients ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research